Comparison of Mac‐2 binding protein glycosylation isomer (M2BPGi) with AST to platelet ratio index (APRI), fibrosis 4 Score (FIB‐4), and nonalcoholic fatty liver disease (NAFLD) fibrosis score (NFS) for NAFLD patients

Abstract

The serum level of Mac-2 binding protein glycosylation isomer (M2BPGi) has been found to increase with the severity of liver fibrosis in biopsy-proved nonalcoholic fatty liver disease (NAFLD). However, the comparison of M2BPGi with noninvasive fibrosis markers such as AST to platelet ratio index (APRI), Fibrosis 4 Score (FIB-4), and NAFLD fibrosis score (NFS) in NAFLD patients remains unclear. The participants of Tzu Chi NAFLD cohort (TCNC) including health controls or NAFLD patients were enrolled in Taipei Tzu Chi Hospital. NAFLD was defined as fatty liver in imaging without hepatitis B virus (HBV), hepatitis C virus (HCV), drug, alcohol, or other known causes of chronic liver disease. A total of 777 subjects were included for final analysis.The serum levels of M2BPGi correlated with APRI, FIB-4 score, and NFS, respectively (P < .001). Of them, 376 (48.4%) were NAFLD patients and 401 were healthy controls. In the group of health controls or NAFLD patients, the M2BPGi levels were significantly higher in female subjects than those of male subjects (P = .027 and 0.006, respectively). Categorized by age, the levels of M2BPGi were significantly higher in elder age groups either in healthy controls or NAFLD patients (P < .05). Compared with healthy controls, NAFLD patients had significantly higher levels of BMI, waist circumference, metabolic components, and liver fibrosis markers such as APRI, NFS, and M2BPGi (P < .05), but no difference in FIB-4 score (P = .685). According to FIB-4 score, "intermediateor high-risk group" had higher APRI, NFS, and M2BPGi than low-risk group. The serum M2BPGi levels correlated with three noninvasive biomarkers of liver fibrosis including APRI, FIB-4 score, and NFS. They were significantly higher in female or elder population. Furthermore, APRI, NFS, and M2BPGi were different between NAFLD patients and healthy controls, but no FIB-4 score. According to FIB-4 score to determine the risk of liver fibrosis, APRI, NFS, and M2BPGi were also different between low risk and

Revisiting Mac-2-Binding Protein Glycosylation Isomer (M2BPGi) for Diagnosing High-Risk Liver Fibrosis: A Stepwise Diagnostic Analysis

“…5,9,10,12,14 Cheng et al found that aging increases M2BPGi levels in healthy patients. 17 This finding may explain why our cut-off results were more than one. However, the effects aging on M2BPGi levels require further research.…”

“…It has been demonstrated that M2BPGi is a good biomarker for evaluating liver fibrosis. [4][5][6][7][8][9][10][11][12][13][14][15][16][17] A stepwise diagnostic analysis has not yet been conducted to determine the value of M2BPGi in assessing liver fibrosis. Here, we aimed to investigate the use of M2BPGi as a single or combined diagnostic modality for liver fibrosis in CHB patients through a stepwise diagnostic analysis.…”

“…3,4 M2BPGi has been widely used to predict liver fibrosis and cirrhosis in different chronic liver diseases. [4][5][6][7][8][9][10][11][12][13][14][15][16][17] In several previous studies, M2BPGi helped to diagnose liver fibrosis in a CHB population 5,10 and it could be used as a single predictor variable to diagnose liver fibrosis grade. 11,12 This marker could also complement and be used with other modalities.…”

Revisiting Mac-2-Binding Protein Glycosylation Isomer (M2BPGi) for Diagnosing High-Risk Liver Fibrosis in Chronic Hepatitis B Patients: A Stepwise Diagnostic Analysis

“… 4 , 5 M2BPGi has been widely used to predict liver fibrosis and cirrhosis in different chronic liver diseases. 5 – 18 In several previous studies, M2BPGi helped to diagnose liver fibrosis in a CHB population 6 , 11 and it could be used as a single predictor variable to diagnose liver fibrosis grade. 12 , 13 This marker could also complement and be used with other modalities.…”

Noninvasive disease severity assessment in nonalcoholic fatty liver disease

“…Cheng et al presented the study results of the correlation of Mac-2 binding protein glycosylation isomer (M2BPGi) serum level with the other documented noninvasive biomarkers or panels in a single-center retrospective NAFLD database. 5 M2BPGi has been vigorously studied as a marker for fibrosis in chronic hepatitis B virus infection, chronic hepatitis C virus infection, nonalcoholic steatohepatitis, and even hepatocellular carcinoma. [6][7][8][9] The cross-sectional study measured the serum levels of the recently-identified glycosylation isoform of Mac-2 binding protein in both NAFLD and healthy controls.…”